Merve Yüksel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Merve Yüksel has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Emine Selin Yıldırım
Department of Internal Medicine, Ankara University School of Medicine, Ankara, Turkey
2 shared publications- Gizem Kumru
Department of Nephrology, Ankara University School of Medicine, Ankara, Turkey
2 shared publications Işınsu Kuzu
Department of Medical Pathology, Ankara University School of Medicine, Ankara, Turkey
2 shared publicationsSaba Kiremitci
Department of Medical Pathology, Ankara University School of Medicine, Ankara, Turkey
2 shared publicationsYasemin Geriş
Department of Internal Medicine, Ankara University School of Medicine, Ankara, Turkey
2 shared publicationsÖnder Arslan
Department of Hematology, Ankara University School of Medicine, Ankara, Turkey
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (8)
IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis
Immunoglobulin heavy chain variable region (IGHV) mutational status and B-cell receptor (BCR) stereotypy are established prognostic markers in chronic lymphocytic leukemia (CLL). However, immunogenetic data from Türkiye and surrounding regions are scarce. We evaluated IGHV mutational status, BCR stereotypy including nearest subset assignment, and their clinical and cytogenetic correlates in a real-world Turkish CLL cohort. We retrospectively analyzed 145 patients with CLL at a tertiary referral center in Türkiye. IGHV mutational status was determined by next-generation sequencing (98% germline homology cutoff). BCR stereotypy was assigned using ARResT/AssignSubsets. Cytogenetic abnormalities were assessed by fluorescence in situ hybridization (FISH). Time-to-first treatment (TTFT), progression-free survival (PFS), and overall survival (OS) were analyzed by Kaplan–Meier method, with multivariate Cox regression for TTFT. Unmutated IGHV was detected in 55.2% of patients, higher than Western reports but consistent with Mediterranean and Middle Eastern cohorts. Unmutated cases showed adverse cytogenetics—del(11q) and multiple concurrent FISH abnormalities—whereas del(13q) predominated in mutated cases. At a median follow-up of 43.0 months unmutated status strongly predicted a profoundly shorter median TTFT compared to mutated cases (17.0 vs. 70.0 months; p < 0.0001). Notably, while an unmutated IGHV status strongly predicted a significantly shorter TTFT, it did not translate into worse PFS or OS compared to mutated cases, reflecting the transformative real-world impact and rescue capacity of modern targeted therapies utilized upon disease progression. Major stereotyped subsets were present in 15.9% of patients; subset #2 was absent, while subset #1 was predominant (39.1%). Subsets #1 and #64B were overrepresented among relapsed cases. Nearest subset #77 showed rapid progression despite mutated IGHV. CLL in Türkiye demonstrates region-specific immunogenetic features while preserving established clinico-biological correlations. Integration of IGHV status, cytogenetics, and BCR stereotypy may improve risk stratification in underrepresented populations.
- 3 June 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (8)
Open AccessIGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis
Immunoglobulin heavy chain variable region (IGHV) mutational status and B-cell receptor (BCR) stereotypy are established prognostic markers in chronic lymphocytic leukemia (CLL). However, immunogenetic data from Türkiye and surrounding regions are scarce. We evaluated IGHV mutational status, BCR stereotypy including nearest subset assignment, and their clinical and cytogenetic correlates in a real-world Turkish CLL cohort. We retrospectively analyzed 145 patients with CLL at a tertiary referral center in Türkiye. IGHV mutational status was determined by next-generation sequencing (98% germline homology cutoff). BCR stereotypy was assigned using ARResT/AssignSubsets. Cytogenetic abnormalities were assessed by fluorescence in situ hybridization (FISH). Time-to-first treatment (TTFT), progression-free survival (PFS), and overall survival (OS) were analyzed by Kaplan–Meier method, with multivariate Cox regression for TTFT. Unmutated IGHV was detected in 55.2% of patients, higher than Western reports but consistent with Mediterranean and Middle Eastern cohorts. Unmutated cases showed adverse cytogenetics—del(11q) and multiple concurrent FISH abnormalities—whereas del(13q) predominated in mutated cases. At a median follow-up of 43.0 months unmutated status strongly predicted a profoundly shorter median TTFT compared to mutated cases (17.0 vs. 70.0 months; p < 0.0001). Notably, while an unmutated IGHV status strongly predicted a significantly shorter TTFT, it did not translate into worse PFS or OS compared to mutated cases, reflecting the transformative real-world impact and rescue capacity of modern targeted therapies utilized upon disease progression. Major stereotyped subsets were present in 15.9% of patients; subset #2 was absent, while subset #1 was predominant (39.1%). Subsets #1 and #64B were overrepresented among relapsed cases. Nearest subset #77 showed rapid progression despite mutated IGHV. CLL in Türkiye demonstrates region-specific immunogenetic features while preserving established clinico-biological correlations. Integration of IGHV status, cytogenetics, and BCR stereotypy may improve risk stratification in underrepresented populations.
- Open Access
- 5 February 2026
- Published by Elsevier in Nefrología (English Edition)
- Vol. 46 (1) , 501363
ANCA positive pauci-immune glomerulonephritis as presenting feature of mantle cell lymphoma: A case report and review of literature
- 5 February 2026
- Published by Elsevier in Nefrología (English Edition)
- Vol. 46 (1) , 501363
Open AccessANCA positive pauci-immune glomerulonephritis as presenting feature of mantle cell lymphoma: A case report and review of literature
- Open Access
- 29 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (35) , e44084
The effect of oral ferrous sulfate use in different posology on laboratory values and clinical findings related to iron metabolism in anemia due to iron deficiency
Iron deficiency anemia (IDA) is a common general health problem in daily clinical practice. A large amount of iron in the body is used for hemoglobin (Hb) synthesis and iron is critical for many biological functions such as cell proliferation, energy production, DNA synthesis and respiration. In recent years, with a better understanding of iron metabolism; it has led to the need to review treatment regimens in the treatment of IDA. Based on these data, we aimed to evaluate the efficacy of oral ferrous sulfate treatment with different doses and posology, its relationship with hepcidin, treatment compliance and gastrointestinal side effects in premenopausal women diagnosed with IDA. Our study was a prospective observational study and included premenopausal female patients aged 18 to 50 years diagnosed with IDA. The patients, who were started on oral ferrous sulfate treatment with different posology and dose, were divided into 3 groups as 2*1 day in the first group, 1*1 day in the second group and 1*1 every other day in the third group and their treatment was completed for 3 months. Changes in Hb and hepcidin were evaluated before treatment and in the second week, and changes in ferritin, transferrin saturation %, total iron binding capacity, and Hb were evaluated in the 3rd month. Significant Hb increase was observed at the end of the second week ( P < .01) and the mean Hb increase was 1.38 ± 1.04 and 1.03 ± 0.48 and ≥1 g/dL in the first and second groups, respectively, while it was 0.69 ± 0.36 and < 1 g/dL in the group given every other day ( P = .020, P = .019, respectively). At the end of the 3rd month, there was a significant increase in Hb level in all 3 groups ( P < .001) and Hb increase was similar between the groups ( P > .05). When the change in ferritin was analyzed, it was observed that ferritin was statistically significantly higher in the first group (2*1) compared to the second and third groups ( P < .05). There was no difference between group 2 and group 3 in terms of ferritin change values ( P > .05). The increase in transferrin saturation % and decrease in total iron binding capacity were similar in all 3 groups at the end of treatment ( P > .05). The change between the second week and baseline hepcidin was observed most in the second group ( P = .024) and the change in hepcidin was similar between the 3 groups ( P = .708). Gastrointestinal side effects were observed more in the first group receiving 2*1 than in the second and third groups ( P < .05). Patients in groups 1 and 2 showed a similar increase in appetite and weight at the end of treatment ( P > .05), whereas no increase in appetite and weight was observed in group 3. In our study, Hb increase of ≥ 1 g/dL in the first and second treatment groups and < 1 g/dL in the third treatment group was observed at the end of the second week; at the end of treatment, anemia improved significantly and Hb increase was similar in all 3 groups. However, due to the gastrointestinal side effects that were significant in the first group, we think that 1*1 daily or 1*1 every other day instead of 2*1 would be more appropriate. In addition, we think that serial hepcidin measurements would give a better idea about the kinetics. Larger studies may emphasize the importance of alternative iron treatment regimens.
- 29 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (35) , e44084
Open AccessThe effect of oral ferrous sulfate use in different posology on laboratory values and clinical findings related to iron metabolism in anemia due to iron deficiency
Iron deficiency anemia (IDA) is a common general health problem in daily clinical practice. A large amount of iron in the body is used for hemoglobin (Hb) synthesis and iron is critical for many biological functions such as cell proliferation, energy production, DNA synthesis and respiration. In recent years, with a better understanding of iron metabolism; it has led to the need to review treatment regimens in the treatment of IDA. Based on these data, we aimed to evaluate the efficacy of oral ferrous sulfate treatment with different doses and posology, its relationship with hepcidin, treatment compliance and gastrointestinal side effects in premenopausal women diagnosed with IDA. Our study was a prospective observational study and included premenopausal female patients aged 18 to 50 years diagnosed with IDA. The patients, who were started on oral ferrous sulfate treatment with different posology and dose, were divided into 3 groups as 2*1 day in the first group, 1*1 day in the second group and 1*1 every other day in the third group and their treatment was completed for 3 months. Changes in Hb and hepcidin were evaluated before treatment and in the second week, and changes in ferritin, transferrin saturation %, total iron binding capacity, and Hb were evaluated in the 3rd month. Significant Hb increase was observed at the end of the second week ( P < .01) and the mean Hb increase was 1.38 ± 1.04 and 1.03 ± 0.48 and ≥1 g/dL in the first and second groups, respectively, while it was 0.69 ± 0.36 and < 1 g/dL in the group given every other day ( P = .020, P = .019, respectively). At the end of the 3rd month, there was a significant increase in Hb level in all 3 groups ( P < .001) and Hb increase was similar between the groups ( P > .05). When the change in ferritin was analyzed, it was observed that ferritin was statistically significantly higher in the first group (2*1) compared to the second and third groups ( P < .05). There was no difference between group 2 and group 3 in terms of ferritin change values ( P > .05). The increase in transferrin saturation % and decrease in total iron binding capacity were similar in all 3 groups at the end of treatment ( P > .05). The change between the second week and baseline hepcidin was observed most in the second group ( P = .024) and the change in hepcidin was similar between the 3 groups ( P = .708). Gastrointestinal side effects were observed more in the first group receiving 2*1 than in the second and third groups ( P < .05). Patients in groups 1 and 2 showed a similar increase in appetite and weight at the end of treatment ( P > .05), whereas no increase in appetite and weight was observed in group 3. In our study, Hb increase of ≥ 1 g/dL in the first and second treatment groups and < 1 g/dL in the third treatment group was observed at the end of the second week; at the end of treatment, anemia improved significantly and Hb increase was similar in all 3 groups. However, due to the gastrointestinal side effects that were significant in the first group, we think that 1*1 daily or 1*1 every other day instead of 2*1 would be more appropriate. In addition, we think that serial hepcidin measurements would give a better idea about the kinetics. Larger studies may emphasize the importance of alternative iron treatment regimens.
- Open Access
- 11 June 2025
- Published by Elsevier in Nefrología
- Vol. 46 (1)
ANCA positive pauci-immune glomerulonephritis as presenting feature of mantle cell lymphoma: A case report and review of literature
- 11 June 2025
- Published by Elsevier in Nefrología
- Vol. 46 (1)
Open AccessANCA positive pauci-immune glomerulonephritis as presenting feature of mantle cell lymphoma: A case report and review of literature
- 20 January 2023
- Published by Galenos Yayinevi in Journal of Ankara University Faculty of Medicine
- Vol. 75 (4) , 525-529
The Relation of Hepcidin, Vitamin D and Inflammatory Parameters, and Effects on Intensive Care Unit Outcome in Critically Ill COVID-19 Patients
- 20 January 2023
- Published by Galenos Yayinevi in Journal of Ankara University Faculty of Medicine
- Vol. 75 (4) , 525-529
The Relation of Hepcidin, Vitamin D and Inflammatory Parameters, and Effects on Intensive Care Unit Outcome in Critically Ill COVID-19 Patients